223 related articles for article (PubMed ID: 33641864)
1. The Microenvironment in Myeloproliferative Neoplasms.
Ramanathan G; Fleischman AG
Hematol Oncol Clin North Am; 2021 Apr; 35(2):205-216. PubMed ID: 33641864
[TBL] [Abstract][Full Text] [Related]
2. Inflammation and myeloproliferative neoplasms.
Lussana F; Rambaldi A
J Autoimmun; 2017 Dec; 85():58-63. PubMed ID: 28669446
[TBL] [Abstract][Full Text] [Related]
3. Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms.
Hoermann G; Greiner G; Valent P
Mediators Inflamm; 2015; 2015():869242. PubMed ID: 26543328
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.
Koschmieder S; Mughal TI; Hasselbalch HC; Barosi G; Valent P; Kiladjian JJ; Jeryczynski G; Gisslinger H; Jutzi JS; Pahl HL; Hehlmann R; Maria Vannucchi A; Cervantes F; Silver RT; Barbui T
Leukemia; 2016 May; 30(5):1018-24. PubMed ID: 26854026
[TBL] [Abstract][Full Text] [Related]
5. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.
Hasselbalch HC; Elvers M; Schafer AI
Blood; 2021 Apr; 137(16):2152-2160. PubMed ID: 33649757
[TBL] [Abstract][Full Text] [Related]
6. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
7. Fecal Microbial Community Composition in Myeloproliferative Neoplasm Patients Is Associated with an Inflammatory State.
Oliver A; El Alaoui K; Haunschild C; Avelar-Barragan J; Mendez Luque LF; Whiteson K; Fleischman AG
Microbiol Spectr; 2022 Jun; 10(3):e0003222. PubMed ID: 35475626
[TBL] [Abstract][Full Text] [Related]
8. Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm.
Fleischman AG
Mediators Inflamm; 2015; 2015():606819. PubMed ID: 26538830
[TBL] [Abstract][Full Text] [Related]
9. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
Marin OyarzĂșn CP; Heller PG
Front Immunol; 2019; 10():1373. PubMed ID: 31258539
[TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative neoplasm stem cells.
Mead AJ; Mullally A
Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
[TBL] [Abstract][Full Text] [Related]
11. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.
Jutzi JS; Mullally A
Front Immunol; 2020; 11():2093. PubMed ID: 32983162
[TBL] [Abstract][Full Text] [Related]
12. The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters.
Catani L; Cavo M; Palandri F
Cells; 2021 Sep; 10(9):. PubMed ID: 34571965
[TBL] [Abstract][Full Text] [Related]
13. [Progress of Study on Cytokines in Myeloproliferative Neoplasms].
Sun CC; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):878-82. PubMed ID: 26117054
[TBL] [Abstract][Full Text] [Related]
14. Role of inflammation in the biology of myeloproliferative neoplasms.
Koschmieder S; Chatain N
Blood Rev; 2020 Jul; 42():100711. PubMed ID: 32505517
[TBL] [Abstract][Full Text] [Related]
15. The Hematopoietic Microenvironment in Myeloproliferative Neoplasms: The Interplay Between Nature (Stem Cells) and Nurture (the Niche).
Zhan H; Kaushansky K
Adv Exp Med Biol; 2020; 1273():135-145. PubMed ID: 33119879
[TBL] [Abstract][Full Text] [Related]
16. Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.
Mendez Luque LF; Blackmon AL; Ramanathan G; Fleischman AG
Curr Hematol Malig Rep; 2019 Jun; 14(3):145-153. PubMed ID: 31119475
[TBL] [Abstract][Full Text] [Related]
17. The Hen or the Egg: Inflammatory Aspects of Murine MPN Models.
Jutzi JS; Pahl HL
Mediators Inflamm; 2015; 2015():101987. PubMed ID: 26543325
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Myeloproliferative Diseases.
Braun LM; Zeiser R
Cells; 2020 Jun; 9(6):. PubMed ID: 32604862
[TBL] [Abstract][Full Text] [Related]
19. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
20. Cytokine Consistency Between Bone Marrow and Peripheral Blood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms.
Chen P; Wu B; Ji L; Zhan Y; Li F; Cheng L; Cao J; Chen H; Ke Y; Min Z; Sun L; Hua F; Chen H; Cheng Y
Front Med (Lausanne); 2021; 8():598182. PubMed ID: 34249954
[No Abstract] [Full Text] [Related]
[Next] [New Search]